All peptides
Tesamorelin
Also known as: Egrifta
FDA-Approved
Tesamorelin is a synthetic GHRH analog approved by the FDA to reduce excess abdominal fat in HIV-associated lipodystrophy.
Buy Tesamorelin on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
Tesamorelin is a synthetic GHRH analog approved by the FDA to reduce excess abdominal fat in HIV-associated lipodystrophy.
FDA Approval Status
Approved by the FDA for at least one medical indication (see approved uses below).
Mechanism of Action
Stimulates pituitary GHRH receptors to increase endogenous GH secretion.
Current Research
Approved based on multiple Phase III trials showing visceral adipose tissue reduction.
Research strength: Strong
Potential Medical Uses
- HIV-associated lipodystrophy (FDA-approved)
Potential Benefits
- Reduces visceral adipose tissue
- Improves lipid profile in target population
Known Side Effects
- Injection-site reactions
- Arthralgia
- Peripheral edema
- Hyperglycemia
Contraindications
- Active malignancy
- Pituitary disorders
- Pregnancy
Drug Interactions
- May affect insulin requirements
- Cortisol-lowering agents
Administration Methods
- Subcutaneous injection, daily
Half-life
~26 minutes
Reconstitution
Supplied with prefilled diluent syringe per prescribing information.
Storage & Handling
Refrigerate; do not freeze.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.